Prestige Consumer Healthcare In (PBH) Q2 2026 earnings — TrendMatrix coverage

Reported EPS

$0.98

Estimate

$0.88

Surprise

+12.0%

Revenue (period 2026-06-30)

$265.7M

Score at report (before → after)

5.8 → 5.8/10

Revenue source: xbrl.

Prestige Consumer Healthcare In (PBH) beat the $0.88 estimate with diluted EPS of $0.98 — a large 12.0% upside surprise. TrendMatrix's engine moved from Buy (Wait) (5.8/10) to Hold at 5.8/10 after the report.

TrendMatrix currently rates PBH Sell at 5.3/10.

1 of the last 4 quarters beat the estimate; this quarter's +12.0% surprise compares with a -3.1% four-quarter average. Next scheduled report: 2026-11-05.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$51.94

Price target

$58.99

Stop

$49.12

Upside to target

+13.6%

Reward-to-risk

2.5:1

Model outputs from TrendMatrix’s engine as of 2026-09-04 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Drug Manufacturers - Specialty & Generic

Market cap

$2.49B

P/E (fwd)

10.3

P/E (ttm)

14.8

52-week range

$42.62–$71.07

Off 52-week high

26.9%

RSI (14)

59

Volume vs avg

0.26×

Score today

5.3/10